99%CAS 148031 -34-9 Eptifibatide Acetate Material Eptifibatide Acetate Powder Eptifibatide Acetate

China 99%CAS 148031-34-9 Eptifibatide Acetate Material Eptifibatide Acetate Powder Eptifibatide Acetate, Find details about China Eptifibatide Acetate, Powder Eptifibatide Acetate from 99%CAS 148031-34-9 Eptifibatide Acetate Material Eptifibatide Acetate Powder Eptifibatide Acetate

Basic Info.

Model NO.

Condavo-Eptifibatide Acetate

Colour

White

Name

Eptifibatide Acetate

Product Name

Eptifibatide Acetate Powder

Color

White Color

Test Method

HPLC UV

Storage

Cool Dry Place

Shelf Life

2 Years

Assay

99%

Grade

Medicine Grade

CAS

148031-34-9

C35h49n11o9s2

831.96200

Density

1.62g/cm3

Melting Point

92-98c

Refractive Index

1.742

COA

Available

Trademark

Condavo

Transport Package

1kg/ Aluminium Bag or 25kg/Drum; as Required

Specification

99%

Origin

Shaanxi

Model NO.

Condavo-Eptifibatide Acetate

Colour

White

Name

Eptifibatide Acetate

Product Name

Eptifibatide Acetate Powder

Color

White Color

Test Method

HPLC UV

Storage

Cool Dry Place

Shelf Life

2 Years

Assay

99%

Grade

Medicine Grade

CAS

148031-34-9

C35h49n11o9s2

831.96200

Density

1.62g/cm3

Melting Point

92-98c

Refractive Index

1.742

COA

Available

Trademark

Condavo

Transport Package

1kg/ Aluminium Bag or 25kg/Drum; as Required

Specification

99%

Origin

Shaanxi

Product Desciption

99%CAS 148031-34-9 Eptifibatide Acetate Material Eptifibatide Acetate powder Eptifibatide Acetate

99%CAS 148031-34-9 Eptifibatide Acetate Material Eptifibatide Acetate Powder Eptifibatide Acetate

Product Name	Eptifibatide Acetate
CAS	148031-34-9
Appearance	White crystalline powder
MF	C35H49N11O9S2
MW	831.96200
Purity	99%
Shelf Life	2 Years

Eptifibatide is a platelet glycoprotein b/a receptor reversible antagonist,adverse reactions are mild , it can be discontinued immediately while adverse reactions occur . It has Strong effect and high selectivity . It has no antigenicity,and it does not cause allergic reactions. It is used For acute coronary syndrome, coronary intervention before treatment and acute Q-wave myocardial infarction. It can relieve unstable angina symptoms and reduce the incidence of cardiovascular events. It can limit the non-Q-wave myocardial infarction,and reduce through wall myocardial infarction occurrance.

99%CAS 148031-34-9 Eptifibatide Acetate Material Eptifibatide Acetate Powder Eptifibatide Acetate

99%CAS 148031-34-9 Eptifibatide Acetate Material Eptifibatide Acetate Powder Eptifibatide Acetate Eptifibatide is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting. Eptifibatide is sometimes given around the clock for up to 4 days in a row.
If you are receiving this injection during an angioplasty procedure, the medicine will be given throughout the entire procedure and for up to 24 hours after the procedure.
Eptifibatide is sometimes given together with aspirin. Follow your doctor's instructions about how much aspirin to take and for how long.
99%CAS 148031-34-9 Eptifibatide Acetate Material Eptifibatide Acetate Powder Eptifibatide Acetate

Etibatide is a glycoprotein (GP) IIb/IIIa receptor (platelet factor I receptor) antagonist. By selectively and reversibly inhibiting the final common pathway of platelet aggregation (plasma coagulation factor I binds to GPIIb/IIIa), the ischemic state due to thrombosis can be reversed.
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodi should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.

99%CAS 148031-34-9 Eptifibatide Acetate Material Eptifibatide Acetate Powder Eptifibatide Acetate